Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis
- 1 November 2000
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 22 (11) , 1357-1369
- https://doi.org/10.1016/s0149-2918(00)83032-5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: Potential for savingsPublished by Elsevier ,1999
- The Rising National Cost of RSV Pneumonia in the Hospital: US Data from 1993-1994Pediatric Research, 1999
- Comments on Palivizumab (Synagis)Published by American Academy of Pediatrics (AAP) ,1999
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Birth Weight and Hospital Readmission of Infants Born PrematurelyArchives of Pediatrics & Adolescent Medicine, 1994
- Rehospitalization of the Very-Low-Birth-Weight InfantAmerican Journal of Diseases of Children, 1981
- EPIDEMIOLOGY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN WASHINGTON, D.C.American Journal of Epidemiology, 1973
- EPIDEMIOLOGY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN WASHINGTON, D.C.American Journal of Epidemiology, 1973
- Epidemiology of Acute Lower Respiratory Disease in ChildrenNew England Journal of Medicine, 1973